Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Show more...
CEO
Blaise Coleman
Dipendenti
2931
Paese
IE
ISIN
IE00BJ3V9050
WKN
000A1XE6M
Quotazioni
0 Comments
Condividi i tuoi pensieri
FAQ
Qual è il prezzo dell'azione Endo International oggi?▼
Il prezzo attuale di ENDPQ è $0 USD — è aumentato del +0% nelle ultime 24 ore. Segui più da vicino l’andamento del titolo Endo International sul grafico.
Qual è il simbolo azionario di Endo International?▼
A seconda della borsa, il simbolo dell’azione può variare. Ad esempio, alla borsa le azioni di Endo International sono negoziate con il simbolo ENDPQ.
Qual è stato il fatturato di Endo International lo scorso anno?▼
I ricavi di Endo International dell'ultimo anno ammontano a 2.01B USD.
Qual è stato l'utile netto di Endo International dell'anno scorso?▼
L'utile netto di ENDPQ per l'anno scorso è di -2.45B USD.
Quanti dipendenti ha Endo International?▼
Al aprile 01, 2026, l'azienda conta 2,931 dipendenti.
In quale settore opera Endo International?▼
Endo International opera nel settore Professional, Scientific, and Technical Services.
Quando Endo International ha completato lo split azionario?▼
Endo International non ha effettuato alcuno split di recente.
Dove si trova la sede di Endo International?▼
La sede di Endo International si trova a Dublin, IE.